Long-term treatment of perennial allergic rhinitis with ipratropium bromide nasal spray 0.06

• Published in: Journal of allergy and clinical immunology 1995, Vol.95 (5), p.1128-1132
• Main Authors: Kaiser, Harold B., Findlay, Steven R., Georgitis, John W., Grossman, Jay, Ratner, Paul H., Tinkelman, David G., Roszko, Paul, Zegarelli, Elena, Wood, Chester C.
• Format: Article
• Language: English
• Subjects: Adolescent; Adult; Aged; Biological and medical sciences; Drug Tolerance; Female; Histamine and antagonists. Allergy; Humans; Ipratropium - administration & dosage; Ipratropium - adverse effects; Ipratropium - therapeutic use; ipratropium bromide; long-term; Longitudinal Studies; Male; Medical sciences; Middle Aged; Nasal Mucosa - drug effects; Nasal Mucosa - metabolism; nasal spray; Nebulizers and Vaporizers; Perennial allergic rhinitis; Pharmacology. Drug treatments; Rhinitis, Allergic, Perennial - drug therapy; rhinorrhea
• ISSN: 0091-6749; 1097-6825
• DOI: 10.1016/S0091-6749(95)70217-2

The purpose of this study was to assess the safety and efficacy of ipratropium bromide nasal spray 0.06% (aqueous solution), 84 μg per nostril three times a day, in reducing nasal hypersecretion in the long-term treatment of patients with perennial allergic rhinitis (PAR). This was an open-label 1-year trial. In the first 6 months all patients were treated with two puffs ipratropium bromide nasal spray 0.06%, 84 μg per nostril three times per day, unless they were unable to tolerate the dose. In the last 6 months the dose could be reduced to the lowest amount required to control rhinorrhea. Ninety-six patients entered the trial, and 47 completed it. Sixty-three patients completed more than 6 months of treatment. Patient and physician global evaluation suggested that ipratropium bromide nasal spray 0.06% is effective in controlling rhinorrhea associated with PAR and can contribute to control of congestion, postnasal drip, and sneezing. There was also a trend toward reduction of mucosal edema and improvement in quality of life. The most common drug-related adverse events were nasal dryness, epistaxis/nose bleed, and increased rhinitis. Most adverse events were mild and resulted in drug discontinuation in less than 10% of patients. Ipratropium bromide nasal spray was well tolerated and not associated with serious drug-related adverse events or clinically significant anticholinergic side effects. Use of ipratropium bromide nasal spray alone or with other standard medications should be considered in treating patients with PAR. (J A LLERGY C LIN I MMUNOL 1995;95:1128-32.)